Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: 26 analysts rate ALNY an overall "Moderate Buy" (19 buys, 1 strong buy, 5 holds, 1 sell) with an average 12‑month price target of about $472.78.
• Recent quarterly results missed estimates—EPS $1.25 vs. $1.43 expected and revenue $1.10B vs. $1.16B expected—although revenue was up 84.9% year‑over‑year.
• Insiders have been net sellers, offloading 38,656 shares (~$12.37M) last quarter; insiders own 1.50% of the stock while institutional investors hold roughly 92.97%.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-six research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $472.7848.

A number of analysts have commented on ALNY shares. Wells Fargo & Company lowered their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an "equal weight" rating for the company in a research report on Tuesday, January 20th. Chardan Capital reaffirmed a "buy" rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. HC Wainwright reaffirmed a "buy" rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Weiss Ratings cut Alnylam Pharmaceuticals from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday, April 6th. Finally, Needham & Company LLC lowered their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating for the company in a research report on Thursday, February 12th.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $305.54 on Friday. The stock has a 50-day moving average of $322.07 and a two-hundred day moving average of $381.65. Alnylam Pharmaceuticals has a one year low of $240.00 and a one year high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The stock has a market cap of $40.77 billion, a P/E ratio of 178.68 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the firm posted ($0.65) EPS. The business's revenue was up 84.9% compared to the same quarter last year. As a group, research analysts predict that Alnylam Pharmaceuticals will post 6.75 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 2,206 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the transaction, the executive vice president owned 64,273 shares of the company's stock, valued at $21,059,048.45. The trade was a 3.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the business's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total value of $528,193.96. Following the completion of the transaction, the executive vice president directly owned 21,860 shares of the company's stock, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 38,656 shares of company stock worth $12,370,696 in the last quarter. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ALNY. Root Financial Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $25,000. MV Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $27,000. HM Payson & Co. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $27,000. Finally, Golden State Wealth Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 36 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.